Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06899165 · ClinicalTrials.gov registry record · Phase 2

Psilocybin-Assisted Therapy for Intergenerational Trauma

A Phase 2 study of Depression and Anxiety, sponsored by Rachel Yehuda.

Recruiting
Registry status
Phase 2
Development phase
100
Enrollment target
1
Study location

NCT06899165 is a Phase 2 study of Depression and Anxiety that is actively recruiting participants, run by Rachel Yehuda. The registered enrollment target is 100 participants, below the 786-participant average among 679 other Depression trials with a reported enrollment target (87% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06899165, a Phase 2 study of Depression and Anxiety, is actively recruiting participants, sponsored by Rachel Yehuda.

RECRUITING
Registry status
Phase 2
Development phase
100 participants
Enrollment target
1
Study location

Study Summary

This is an open-label psilocybin-assisted therapy study that will examine the safety and tolerability of psilocybin-assisted therapy in the offspring of genocide survivors with mood and anxiety disorders. The study will also investigate the efficacy of psilocybin-assisted therapy in reducing symptoms such as depression, anxiety and stress, as well as changes to the psychological effects of parental exposure to genocide, and changes to psychological resilience.

Interventions

  • DRUG Psilocybin
  • BEHAVIORAL Integration sessions

Study Locations (1)

New York

  • The Parsons Research Center for Psychedelic Healing - New York

Trial Details

FieldValue
Enrollment Target 100 participants
Start Date 2025-08-28
Est. Completion 2030-01-02
Phase Phase 2

Sponsor

Rachel Yehuda

3 total trials

What the Registry Record Tells You About NCT06899165

The ClinicalTrials.gov registry entry for NCT06899165 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 786-participant average among 679 other Depression trials with a reported enrollment target (87% lower). The listed sponsor is Rachel Yehuda, which has 3 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Depression appearing as the primary indexed condition, and to 2 interventions - of which Psilocybin is the first listed.

NCT06899165 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.

Frequently Asked Questions

What is clinical trial NCT06899165 about?

NCT06899165 is a clinical study titled "Psilocybin-Assisted Therapy for Intergenerational Trauma". This is an open-label psilocybin-assisted therapy study that will examine the safety and tolerability of psilocybin-assisted therapy in the offspring of genocide survivors with mood and anxiety disorders. The study will also investigate the efficacy of psilocybin-assisted therapy in reducing sympto...

What is the current status of trial NCT06899165?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 100 participants. The study started on 2025-08-28. Estimated completion is 2030-01-02.

What conditions does trial NCT06899165 study?

This clinical trial studies the following conditions: Depression, Anxiety, Psychological Stress.

What interventions are being tested in trial NCT06899165?

The interventions under investigation include: Psilocybin (DRUG), Integration sessions (BEHAVIORAL).

Who is sponsoring clinical trial NCT06899165?

This trial is sponsored by Rachel Yehuda, which has 3 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06899165 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Depression

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.